These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3779714)

  • 21. A novel, killed-virus nasal vaccinia virus vaccine.
    Bielinska AU; Chepurnov AA; Landers JJ; Janczak KW; Chepurnova TS; Luker GD; Baker JR
    Clin Vaccine Immunol; 2008 Feb; 15(2):348-58. PubMed ID: 18057181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Shimizu Y; Takai Y; Wakamiya N; Ueda S; Kato S; Hamaoka T
    Eur J Immunol; 1984 Feb; 14(2):171-5. PubMed ID: 6199215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans.
    Demkowicz WE; Maa JS; Esteban M
    J Virol; 1992 Jan; 66(1):386-98. PubMed ID: 1727494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccinia virus proteins on the plasma membranes of infected cells. II. Expression of viral antigens and killing of infected cells by vaccinia virus-specific cytotoxic T cells.
    Mallon VR; Domber EA; Holowczak JA
    Virology; 1985 Aug; 145(1):1-23. PubMed ID: 3874471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.
    Yoshioka T; Fujiwara H; Takai Y; Ogata M; Shimizu J; Hamaoka T
    Cancer Immunol Immunother; 1987; 24(1):8-12. PubMed ID: 3493074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen.
    Acres RB; Hareuveni M; Balloul JM; Kieny MP
    J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):136-43. PubMed ID: 8280702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
    Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
    J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitization of human tumor cells to homologous complement by vaccinia virus treatment.
    Okada H; Wakamiya N; Okada N; Kato S
    Cancer Immunol Immunother; 1987; 25(1):7-9. PubMed ID: 3594492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.
    Sakamoto K; Yoshioka T; Shimizu J; Sato S; Nakajima H; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1988 Jan; 79(1):99-108. PubMed ID: 3128511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The bovine herpesvirus type 1 major tegument protein VP8 expressed in recombinant vaccinia virus does not induce significant immunity in mice.
    LaBoissière S; Trudel M; Simard C
    Virus Res; 1996 Feb; 40(2):191-8. PubMed ID: 8725115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppressive effect of portal venous inoculation with tumor cells on the anti-tumor immune potential.
    Kokudo S; Qian JH; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1987 Sep; 78(9):946-51. PubMed ID: 3117751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant.
    Ludvíková V; Kunke D; Hamsíková E; Kutinová L; Vonka V
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1445-9. PubMed ID: 1646285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.
    Hostetler LW; Romerdahl CA; Kripke ML
    Cancer Res; 1989 Mar; 49(5):1207-13. PubMed ID: 2465081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130.
    Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells.
    Tsuchiya Y; Igarashi M; Suzuki R; Kumagai K
    J Immunol; 1988 Jul; 141(2):699-708. PubMed ID: 2968407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.